The stock of Hepion Pharmaceuticals Inc (HEPA) has gone down by -34.73% for the week, with a -38.51% drop in the past month and a -57.04% drop in the past quarter. The volatility ratio for the week is 22.91%, and the volatility levels for the past 30 days are 14.66% for HEPA. The simple moving average for the past 20 days is -35.46% for HEPA’s stock, with a -64.72% simple moving average for the past 200 days.
Is It Worth Investing in Hepion Pharmaceuticals Inc (NASDAQ: HEPA) Right Now?
Additionally, the 36-month beta value for HEPA is 1.71. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for HEPA is 6.95M and currently, short sellers hold a 0.35% ratio of that float. The average trading volume of HEPA on January 22, 2025 was 58.92K shares.
HEPA) stock’s latest price update
The stock of Hepion Pharmaceuticals Inc (NASDAQ: HEPA) has decreased by -31.39 when compared to last closing price of 0.47.Despite this, the company has seen a loss of -34.73% in its stock price over the last five trading days. globenewswire.com reported 2024-12-11 that EDISON, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (Nasdaq: HEPA) (the “Company” or “Hepion”), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, today announced that it has entered into a termination agreement with Pharma Two B Ltd. which terminates the merger agreement between the two parties that was previously entered into on July 19, 2024.
Analysts’ Opinion of HEPA
Many brokerage firms have already submitted their reports for HEPA stocks, with ROTH Capital repeating the rating for HEPA by listing it as a “Buy.” The predicted price for HEPA in the upcoming period, according to ROTH Capital is $14 based on the research report published on July 20, 2020 of the previous year 2020.
HEPA Trading at -44.53% from the 50-Day Moving Average
After a stumble in the market that brought HEPA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.78% of loss for the given period.
Volatility was left at 14.66%, however, over the last 30 days, the volatility rate increased by 22.91%, as shares sank -42.54% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -50.09% lower at present.
During the last 5 trading sessions, HEPA fell by -34.73%, which changed the moving average for the period of 200-days by -87.43% in comparison to the 20-day moving average, which settled at $0.4986. In addition, Hepion Pharmaceuticals Inc saw -31.55% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for HEPA
Current profitability levels for the company are sitting at:
- -260.21 for the present operating margin
- 0.61 for the gross margin
The net margin for Hepion Pharmaceuticals Inc stands at -206.91. The total capital return value is set at -28.58. Equity return is now at value -288.27, with -158.12 for asset returns.
Based on Hepion Pharmaceuticals Inc (HEPA), the company’s capital structure generated 1.22 points at debt to capital in total, while cash flow to debt ratio is standing at -11.72. The debt to equity ratio resting at -5.47. The interest coverage ratio of the stock is -4223.82.
Currently, EBITDA for the company is -49.26 million with net debt to EBITDA at -0.02. When we switch over and look at the enterprise to sales, we see a ratio of 27.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.30.
Conclusion
In conclusion, Hepion Pharmaceuticals Inc (HEPA) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
